Company: LCTX
Filing Date: 2025-01-27
Form Type: 8-K
Source: 0000950170-25-009227
Chunk: 0

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-01-27
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

On January 27, 2025, Lineage Cell Therapeutics, Inc. (the “ Company,” “we,” “us,” or “our”), held a special meeting of shareholders. The matters voted upon at the meeting are described in detail in our definitive proxy statement for the meeting, filed with the U. S. Securities and Exchange Commission (the “ SEC”) on December 9, 2024. Below is a brief description of each such matter and the final voting results, including the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number.

1.

Shareholders approved, for purposes of complying with NYSE American LLC listing standards and requirements, the issuance of our common shares and common warrants pursuant to the terms of the securities purchase agreement, dated November 19, 2024, between us and Broadwood Partners, L. P., and our common shares issuable upon exercise of such common warrants.

    Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ─────────────────────────────────────────────────────────────────────────
  114,132,309          6,732,082          362,083                     0  

2.

Shareholders approved the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of proposal 1 if there were not sufficient votes to approve such proposal at the time of the meeting or any adjournment or postponement thereof.

    Votes For      Votes Against      Abstentions      Broker Non-Votes  
 ─────────────────────────────────────────────────────────────────────────
  112,392,014          8,458,712          375,748                     0  

Item 7.01 Regulation FD Disclosure.